Equestive details and FDA ambiguity

Jim explains the FDA letter's unspecified deficiencies, cash runway, and why selling now might be premature for holders.

Play episode from 22:10

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!